Pfizer Tackles Antimicrobial Resistance
Modern medicine depends on antibiotics to help prevent and treat infections. Alarmingly, many are losing their effectiveness due to antimicrobial resistance (AMR).
If antibiotics become ineffective, common infections could result in hospitalization or death. Life-saving interventions and routine procedures would become more difficult or impossible.
AMR can affect anyone. It causes 700,000 deaths annually worldwide, a number projected to skyrocket to 10 million by 2050 without intervention.
Pfizer is proud to partner with the infectious disease community and play a leading role in the fight against AMR through:
- Active stewardship
- Innovative surveillance tools, like ATLAS (Antimicrobial Testing Leadership and Surveillance)
- Global policy leadership
- A diverse portfolio of anti-infective medicines and vaccines
- Responsible manufacturing practices
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families